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Introduction: Multipotent stromal cells (MSCs) are among the key candidates in regenerative medicine. However
variety of MSC sources and general heterogeneity lead to controversial data in functional characterization.
Furthermore, despite intensive usage as preclinical animal model, little is known about MSCs of the common
marmoset monkey.
Methods: MSCs derived from placental amnion and bone marrow samples from human and common marmoset
were characterized in parallel over 12 passages to monitor similarities and significant differences (p ≤ 0.05, Student’s
t-test) in MSC markers and major histocompatibility complex (MHC) class I expression by immunohistochemistry,
flow cytometry, real-time PCR, metabolic activity test, with special focus on pluripotency associated genes.
Results: Human and non-human primate MSCs were characterized for expression of MSC markers and capability of
differentiation into mesenchymal lineages. MSCs could be cultured more than 100 days (26 passages), but metabolic
activity was significantly enhanced in amnion vs. bone marrow MSCs. Interestingly, MHC class I expression is significantly
reduced in amnion MSCs until passage 6 in human and marmoset, but not in bone marrow cells. For MSC markers,
CD73 and CD105 levels remain unchanged in amnion MSCs and slightly decline in bone marrow at late passages;
CD166 is significantly higher expressed in human MSCs, CD106 significantly lower vs. marmoset. All cultured MSCs
showed pluripotency marker expression like Oct-4A at passage 3 significantly decreasing over time (passages 6–12)
while Nanog expression was highest in human bone marrow MSCs. Furthermore, human MSCs demonstrated the
highest Sox2 levels vs. marmoset, whereas the marmoset exhibited significantly higher Lin28A values. Bisulfite
sequencing of the Oct-4 promoter region displayed fewer methylations of CpG islands in the marmoset vs. human.
Conclusions: Little is known about MSC characteristics from the preclinical animal model common marmoset vs.
human during long term culture. Studied human and common marmoset samples share many similar features such as
most MSC markers and reduced MHC class I expression in amnion cells vs. bone marrow. Furthermore, pluripotency
markers indicate in both species a subpopulation of MSCs with true ‘stemness’, which could explain their high
proliferation capacity, though possessing differences between human and marmoset in Lin28A and Sox2 expression.* Correspondence: mueller.thomas@mh-hannover.de
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Multipotent stromal cells (MSCs) are among the key
candidates in the broad perspective of application in the
field of regenerative medicine, tissue engineering, and
cell replacement therapy. This status is determined by
their relative availability from various sources, high plas-
ticity, and immunomodulatory properties. Unlike the
other promising candidates, such as embryonic stem
cells (ESCs), MSCs do not face ethical and legislative is-
sues and do not have modified genotypes, as in the in-
duced pluripotent stem cells (iPSCs), which makes
MSCs more realistic for clinical usage in the near future.
Among many varying definitions, MSCs are to date de-
fined as a class of cells with the potential to self-renew
and with certain “stemness” abilities, mostly to differen-
tiate into multiple cell lineages within the same germ
layer [1]. Furthermore, MSCs display a spindle-shaped
morphology, are adherent to plastic, and are positive for
certain surface markers, such as CD106+, CD105+, CD90
+, CD73+, CD71+, CD44+, and CD29+, while being nega-
tive for hematopoietic markers, such as CD34− and
CD45− [2, 3]. Yet marker combinations can vary de-
pending on the variety of sources for isolation, resulting
in a broad diversity and heterogeneity of obtained cell
populations. Isolation of MSCs often implies invasive
procedures and mostly does not result in large-scale
numbers of cells. However, stromal cells of placenta and
bone marrow, obtained by natural delivery and apher-
esis, provide one of the most reliable and abundant
sources of MSCs [4]. Probably owing to the variety of
MSC sources, as well as the heterogeneity of the derived
cell populations in primary cultures, many controversial
results exist from different groups in terms of various
functions and the general characterization of MSCs
[5–7]. Some authors question the proliferation capacities
of placental MSCs compared with those from bone mar-
row, arguing that the placenta is a temporal organ with
terminated postnatal function. Nevertheless, over the
last decades placental MSCs have attracted attention in
the field of research as well as in clinical application,
which is determined by the virtual absence of ethical
concerns and ease of access [8]. Furthermore, there are
divergent reports about possible culture duration of
MSCs [1, 6, 9] and changes in the expression of MSC
markers and major histocompatibility complex (human
leukocyte antigen (HLA)/MHC class I, which is a major
obstacle in transplantation) over time [6, 10]. Lastly, the
expression of pluripotency genes such as Oct-4A, Nanog,
Sox2, Klf4, and c-Myc in MSCs is still discussed contro-
versially [9, 11–14].
To address these topics, in this study we performed a
comprehensive characterization of MSCs derived from
human placental amnion and bone marrow over time in
culture. Parallel to the human study, we utilized cellsfrom our animal model, a small Brazilian nonhuman pri-
mate (common marmoset monkey, Callithrix jacchus),
which is readily used as a preclinical model with the
possibility of mimicking numerous pathologies, includ-
ing various neurodegenerative and immune-relevant dis-
eases, which are inherent to human and other primates
[15]. While ESC and iPSC lines from C. jacchus are well
established and characterized [16–19], little is known
about the marmoset MSCs, especially in comparison
with such cells of a human origin.Materials and methods
Retrieval of tissue
In the case of the human, three samples of bone marrow
were obtained during routine surgeries at Hannover
Medical School in the Department of Orthopaedic Sur-
gery, approved by the Ethical Commission of Hannover
Medical School (ethic votum No. 565–2009). Five hu-
man placentas were donated anonymized after routine
Caesarian-section birth in the Department of Gynecology
at Hannover Medical School, Hannover, Germany and ap-
proved by the Ethical Commission of Hannover Medical
School (ethic votum No. 2396–2014). All human samples
were obtained in an anonymized form with consent from
the patients. In the case of the nonhuman primate model,
obtaining three samples of bone marrow (post mortem)
and five samples of placenta (post natal) from healthy
marmosets was approved by Institutional Animal Care
from the Centre of Reproductive Medicine and Andrology
(CeRA), Muenster, Germany. Placenta samples were
collected after natural birth at CeRA.Isolation of marmoset bone marrow stromal cells
The bone marrow of marmoset was isolated post mor-
tem by rupture of the tibia and femur of each animal
immediately after death had been confirmed by a veter-
inarian. The cavity was flushed with a hypodermic nee-
dle attached to a syringe. For preventing coagulation and
for cell singularization, a heparin phosphate-buffered sa-
line (PBS) mix was utilized (5 IU/ml) and the bone
marrow was separated by pipetting thoroughly for 3
minutes. After singularization, the cell suspension was
transferred into red cell lysis buffer (NH4Cl 0.15 M,
KHCO3 10 mM, ethylenediaminetetraacetic acid (EDTA)
0.1 mM, pH 7.5) for 5 minutes and centrifuged at 200 × g
for 10 minutes. The cell pellet was resuspended in the
MSC culture medium consisting of Dulbecco’s Modified
Eagle Medium (DMEM; Biochrom AG, Berlin, Germany),
15 % fetal calf serum (FCS; Biochrom AG), 1 % penicillin/
streptomycin (Invitrogen GmbH, Karlsruhe, Germany),
and 50 μM L-ascorbic acid-2-phosphate and plated on a
cell culture dish (Greiner Bio-One GmbH, Frickenhausen,
Germany).
Table 1 Antibodies used with corresponding working dilutions
and origin
CD antigen Company Catalogue
number
Dilution
Brachyury Abcam (Cambridge, UK) ab20680 1:100






CD73 Abcam (Cambridge, UK) 7G2 ab54217 1:250
CD 34 Beckman Coulter (Brea,
CA, USA)
PN IM1167 1:50
Snail1 Santa Cruz (Dallas, TX, USA) sc-28199 1:100













MHC, major histocompatibility complex
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Bone marrow aspirates were obtained by iliac crest as-
piration during routine orthopedic procedures from
three healthy donors. Human MSCs were isolated from
fresh heparinized bone marrow aspirates by density gra-
dient centrifugation and subsequent recovery of mo-
nonuclear cells. Cells were washed with PBS, then
resuspended in MSC medium (DMEM; Biochrom AG),
10 % FCS Hyclone (Thermo Fisher Scientific, Schwerte,
Germany), 1 % penicillin/streptomycin (Biochrom AG),
and 2 ng/ml human recombinant fibroblast growth fac-
tor (FGF)-2 (PeproTech GmBH, Hamburg, Germany)
and cultured at 37 °C with 5 % CO2 at 85 % humidity.
Plastic-adherent cells were propagated as described pre-
viously [20].
Cell isolation from placenta
Amnion membranes were washed with PBS with 10 %
Ciprofloxacin (Fresenius Kabi, Bad Homburg, Germany),
cut into small pieces, and incubated in the presence of
0.25 % trypsin for 1 hour at 37 °C. After trypsin diges-
tion, samples were filtered through 100 μm cell strainer
(BD Biosciences, Durhan, NC, USA), the cell suspension
was centrifuged for 5 minutes at 300 × g (Heraeus Mul-
tifuge 1S-R; Thermo Fisher Scientific), and the cell pellet
was resuspended in MSC growth medium and plated
into 10 cm cell dishes (Cellstar; Greiner Bio-One
GmbH). All cell samples were tested for mycoplasma
contamination. With regard to the monoplacental nature
of pregnancy, amniotic membranes from the marmoset
were retrieved exactly around each umbilical cord to
avoid a mixture of cells from different fetuses.
Flow cytometry
After trypsinization and fixation in 4 % paraformalde-
hyde, cells were aliquoted into fluorescence-activated
cell sorting (FACS) tubes and stained with antibodies.
Cells incubated with secondary antibody were used as
controls. Cells were incubated at room temperature with
primary and secondary antibody for 1 hour respectively.
After each step, cells were washed twice in PBS and then
measured with a flow cytometer (FACSCalibur™; Becton
Dickinson GmbH, Heidelberg, Germany) with a rate of
10,000 events per measurement. Cells incubated only
with a secondary antibody were used as a negative con-
trol. BD CellQuest™ Pro software (version 6.0; Becton
Dickinson GmbH) was used for analysis of the data with
a regional statistics approach.
Antibodies
Information on primary and secondary antibodies used
for flow cytometry and immunohistochemistry (IHC)
experiments is presented in Table 1.Immunohistochemical staining
For IHC staining, the Dako LSAB+System-HRP kit was
used (Dako North America, Carpinteria, CA, USA). For
the examination for mesenchymal markers, 2 × 104
cells/well of each sample were seeded on a glass slide
(20 mm in diameter) in a 12-well plate (Greiner Bio-
One GmbH) and then fixed with 4 % paraformaldehyde
after 24 hours. After washing in PBS, six drops of 3 %
hydrogen peroxide were added to each well for 5 mi-
nutes to block endogenous peroxidase activities. The
cells were incubated with respective biotinylated anti-
body overnight at 4 °C. The link solution was then ap-
plied to the glass slides for 30 minutes followed by
streptavidin peroxidase for 30 minutes. The substrate so-
lution was added to each well and incubated for 7–15
minutes until positive signals were visible on the glass
slides. Then cells were washed twice with 1 ml distilled
water. For a nuclei counterstaining, 300 μl hematoxylin
were added and incubated for 3–5 minutes. After a last
washing step with distilled water, the glass slides were
transferred upside down onto an object plate in one
drop of Mowiol® 4–88 (Sigma-Aldrich GmbH, Seelze,
Germany) and dried overnight in the dark. Images were
taken using a Keyence Biozero microscope (Keyence
Germany GmbH, Neu-Isenburg, Germany).
Total RNA isolation and RT-PCR
RNA was extracted using the peqGOLD Total RNA Kit
(Peqlab GmbH, Erlangen, Germany). Briefly, after trypsi-
nization the pellet was lysed in 400 μl RNA lysis buffer
and transferred to a DNA removing column to remove
contaminant DNA. After centrifugation at 12,000 × g for
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through. The lysate was loaded onto a Perfect Bind RNA
Column and centrifuged at 10,000 × g for 1 minute to
bind the RNA to the column. After a washing step with
500 μl RNA Wash Buffer I and washing twice with 600 μl
RNA Wash Buffer II, the column was dried by centrifuga-
tion at 10,000 × g for 2 minutes. Finally, the RNA was
eluted from the column by applying 50 μl sterile
RNase-free dH2O. The RNA concentration was mea-
sured with a NanoDrop photometer ND-1000 (Thermo
Scientific, Waltham, MA, USA). Extracted RNA was
transcribed into cDNA using the High Capacity cDNA
Reverse Transcription Kit (Life Technologies GmbH,
Darmstadt, Germany). By adding Oligo(dT) primers
(TIB Molbiol, Berlin, Germany) only the mRNA was
transcribed. For the analysis of the mesenchymal mar-
kers and immunorelevant molecules, a PCR reaction of
30 μl per sample was set up as follows: 24 μl dH2O, 3 μl of
1× PCR buffer (NEB, Frankfurt, Germany), 0.5 Units Taq
polymerase (NEB), 100 mM dNTPs (Fermentas, St. Leon-
Rot, Germany), 20 pmol/μl each primer, and 1 μg cDNA.
Cycling conditions contained a precycling step at 95 °C for
3 minutes followed by 35 cycles of denaturation at 95 °C
for 45 seconds, annealing at each corresponding primer
temperature for 45 seconds, and extension at 72 °C for 90
seconds, with a final extension step at 72 °C for 10 mi-
nutes. In order to verify the product identity of the ob-
tained cDNA fragments of the expected size, the
sequencing performed in house utilizing a BigDye™ Ter-
minator Cycle Sequencing Ready Reaction Kit (v1.1; PE
Applied Biosystems, Waltham, MA, USA) according to the
manufacturer’s instructions in 96-well PCR plates (Kisker,
Steinfurt, Germany) in a C1000 Thermal Cycler (BioRad,
Munich, Germany). A summary of oligonucleotide se-
quences, fragment sizes, and PCR conditions is presented
in Table 2.Real-time PCR
A 1 μl sample containing 10 ng cDNA was added to 19 μl
SYBR Green master mix (Life Technologies GmbH) sup-
plemented with respective forward and reverse primer
concentrations optimized by prior titration and melting
curve analysis for specificity and efficiency in triplicates.
The quantitative PCR was performed using a StepOnePlus
real-time platform (Life Technologies GmbH). Cycling
conditions contained a precycling step at 95 °C for 10 mi-
nutes followed by 40 cycles of denaturation at 95 °C for 15
seconds and annealing at 60 °C for 1 minute. Additionally,
melting curves were analyzed for the specificity of the
products. In cluster comparison with other housekeeper
genes, ribosomal housekeeper gene RPS29 was stable in
our cells and tissues, and was therefore utilized for ΔCt
normalization with additional control tissue skin for2–ΔΔCt analysis. Oligonucleotides were designed from a
consensus sequence from human and marmoset utilizing
the databases from the National Center for Biotechnology
Information (NCBI) and the Wellcome Trust Sanger Insti-
tute/The European Bioinformatics Institute (Ensembl).
Whenever possible, sequences from two different exons
were used to exclude gDNA contaminations (Table 2).
Cell proliferation assay (MTT test)
To evaluate the metabolic activity of human and mar-
moset MSCs through numerous passages in culture, we
applied the Promega CellTiter 96® Non-Radioactive Cell
Proliferation Assay (Promega, Madison, WI, USA). The
cellular reduction of 3-(4.5-dimethylthiazol-2-yl)-2.5-di-
phenyltetrazoliumbromide (MTT) into formazan crystals
is catalyzed by the mitochondria of living cells and is
widely accepted as a marker for the growth and meta-
bolic activity. The assay was performed according to the
manufacturer’s specifications. In brief, 5 × 105 cells of
primary culture were seeded into 10 cm culture dishes
and cultivated for 4 days until confluence with following
repassaging. After each passage, cells were seeded at a
density of 1 × 104 MSCs/well of a 96-well plate (four
parallels for each sample) and cultivated for 24 hours in
100 μl MSC medium (37 °C, 5 % CO2). After 24-hour
incubation, 15 μl MTT reagent per well were added,
incubated for 4 hours at 37 °C, and then 100 μl Stop
Mix reagent was added to each well and incubated for
1 hour at room temperature in the absence of light.
Afterwards, the formazan concentration was measured
at 550–620 nm with an ELISA plate reader (BioRad
680). We compared the proliferation activities of all
studied cell types with each other. The NIH 3T3 fibro-
blast immortal cell line was used as a control with a
constant proliferation activity.
Bisulfite sequencing assay
Evaluation of the methylation status of Oct-3/4 promoter
was performed by the bisulfite conversion method as de-
scribed previously [21]. In brief, bisulfite treatment of
genomic DNA converts unmethylated cytosines into
uracil; respective changes were detected by PCR amplifi-
cation followed by DNA sequencing.
Genomic DNA was produced with the peqGOLD
Tissue DNA Kit (Peqlab BmbH) according to the manu-
facturer’s protocol, from which 200 ng were bisulfite
converted with the EZ DNA Methylation-Direct™ Kit
(Zymo Research, Freiburg, Germany). The fragment of
interest was amplified from converted DNA by RT-PCR
using ZymoTaq™ PreMix (Zymo Research), with oligonu-
cleotides published previously [21]. Respective fragments
were extracted from a 1.5 % agarose gel, ligated into
pGEM-T Vector (Promega) and transformed into JM109
bacteria (Promega). Forty single-bacterium colonies of
Table 2 Oligonucleotides with corresponding accession numbers
Gene Sequence Annealing temperature (°C) Fragment size (base pairs) Accession number
RPS29 5′-CGA AAA TTC GGC CAG GGT TC-3′ 60 109 XM_009006002.1
5′-TCG CGT ACT GAC GGA AAC AC-3′
CD 90 5′-TCC CAG AAC GTC ACT GTG CT-3′ 60 134 ENSCJAT00000027416
5′-AGG GAT ATG AAA TCC GTG GC-3′
CD 44 5′-TGG CCT TGG CTT TGA TTC TT-3′ 60 73 ENSG00000026508
5′-AGC TTT TTC TTC TGC CCA CA-3′
CD 106 5′-TGG ATT CTG TGC CCA CAG AAA-3′ 60 120 ENSCJAT00000006643
5′-TGG TCA CAG AGC CAC CTT CT-3′
CD 166 5′-ACG TGT TTG AGG CAC CTA CAA-3′ 60 94 ENSG00000170017
5′-AGC TGC TCT GTT TCG AGA AAT A-3′
β2m 5′-CGA GAT GGC TAG CTC CGT G-3′ 60 162 XM_002753411.2
5′-GAT GGA TGA AAC CCA GAC AC-3′
Oct 4 hs 5′-GGG TGG AGA GCA ACT CCG A-3′ 60 123 NM_002701.5
5′-GCA GAG CTT TGA TGT CCT GGG-3′
Oct 4 cj 5′-GGG TGG AGA GCA ATT CCG A-3′ 60 123 JQ627833
5′-GCA GAG CTT TGA TGT CTT GGG-3′
Sox 2 5′-ACA TGA ACG GCT GGA GCA A-3′ 60 197 XM_002807565
5′-GTA GGA CAT GCT GTA GGT GGG-3′
Nanog 5′-AGC TGT GTG TAC TCA ATG AT-3′ 60 121 ENSCJAT00000037278
5′-TGG TTC TGG AAC CAG GTC TT-3′
c-Myc 5′-AGC GAC TCT GAG GAG GAA CA-3′ 60 150 XM_002759229
5′-GCA CCT CTT GAG GAC CAG TG-3′
Lin 28 5′-AGT GGT TCA ACG TGC GCA T-3′ 60 181 XM_002751258
5′-TCC AGA CCC TTG GCT GAC TT-3′
Klf 4 5′-TTA ATG AGG CAG CCA CCT GG-3′ 60 145 XM_002806507
5′-AAG TCG CTT CAT GTG GGA GAG-3′
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submitted for sequencing (Eurofins Genomics, Ebersberg,
Germany) and the obtained sequence was compared with
unconverted genomic DNA with application of SnapGene
software (GSL Biotech LLC, Chicago, IL, USA).
Multilineage differentiation assays
The differentiation of MSCs into adipogenic, chondro-
genic, and osteogenic lineages was performed by cultur-
ing cells in specialized culture media. In brief, all studied
MSC samples were seeded with concentration of 5 × 104
cells/well onto six-well culture dishes (Cellstar; Greiner
Bio-One GmbH). Adipogenic differentiation of studied
MSCs was induced by culturing the cells for 14 days in
medium containing 1 μM dexamethasone (Sigma-Al-
drich, St. Louis, MO, USA), 60 μM indomethacin
(Sigma-Aldrich), 0.5 mM 3-isobutyl-1-methylxanthin
(Sigma-Aldrich), 1 % (v/v) penicillin/streptomycin (Bio-
chrom AG), and 10 μg/ml insulin (Sigma-Aldrich) in
DMEM (Biochrom AG) supplemented with 20 mMHEPES zwitterionic buffer (Biochrom AG) and 20 %
FCS HyClone™ (Thermo Fisher Scientific). After cultur-
ing the cells for 14 days, formation of lipid vacuoles was
evaluated with Oil Red O staining. In brief, the cells
were washed with PBS, fixed in 10 % formalin (Sigma-
Aldrich) for 20 minutes, and rinsed twice with water
followed by one final wash with 50 % ethanol (Appli-
Chem GmbH, Darmstadt, Germany). Formed lipid vacu-
oles were detected by incubation for 10 minutes in Oil
Red O (Sigma-Aldrich) in acetone/50 % ethanol (Merck
KGaA, Darmstadt, Germany) and a final rinse with
water. Adipogenic differentiation procedures for each
sample were performed in triplicate and compared with
undifferentiated cell control (n = 3) and visualized with
a bright-field microscope (Keyence Biozero; Keyence,
Osaka, Japan).
Osteogenic differentiation was performed by culturing
cells for 21 days in medium containing 0.1 μM dexa-
methasone, 0.05 mM L-ascorbic acid-2-phosphate
(Sigma-Aldrich), 1 % (v/v) penicillin/streptomycin, and 3
Fig. 1 Typical MSC markers were detected in marmoset and human
amnion MSCs. a–e Marmoset. f–j Human. Immunohistochemically
negative signal for CD34−, but positive signal for CD105+, CD90+, Bra+,
and Snail1+. NC absence of primary antibody
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Roth GmbH, Karlsruhe, Germany) in DMEM LG (Bio-
chrom AG) supplemented with 20 mM HEPES zwitter-
ionic buffer and 10 % FCS HyClone™. After culturing the
cells for 21 days, mineralization of MSCs differentiated
into osteoblasts was detected by Von Kossa staining. In
brief, mineralized cells were washed twice with PBS and
fixed with 10 % formalin, and then washed once with
PBS and twice with double-distilled water (ddH2O)
followed by addition of 1 % silver nitrate (Riedel de
Haen GmbH, Seelze, Germany). After that, the plate was
exposed for 30 minutes to sunlight, washed with ddH2O,
stained with 5 % sodium thiosulfate (Sigma-Aldrich) for
5 minutes, and rinsed again with ddH2O. Osteogenic dif-
ferentiation procedures for each sample were performed
in triplicate and compared with undifferentiated cell
control (n = 3) and visualized with a bright-field micro-
scope (Keyence Biozero).
For chondrogenic differentiation, 2.5 × 105 cells/well
were pelleted in V-shape 96-well plates (Cellstar; Greiner
Bio-One Gmbh) by centrifugation at 200 × g for 5 mi-
nutes. The pellet was incubated for 21 days in chondro-
genic differentiation medium composed of DMEM HG
culture medium ((Biochrom AG) supplemented with 20
mM HEPES buffer with addition of 1 % (v/v) penicillin/
streptomycin, 0.1 μM dexamethasone, 1 % (v/v) ITS Uni-
versal Cell Culture Supplement Premix (Becton Dickinson
GmbH), 0.17 mM L-ascorbin acid-2-phosphate (Sigma-
Aldrich), 1 mM sodium pyruvate (Biochrom AG), 0.35
mM L-proline (Biochrom AG), and 10 ng/ml transform-
ing growth factor-β3 (PeproTech GmbH). The medium
was changed every 3 days. After 3 weeks, the pellet was
fixed with 10 % paraformaldehyde (Carl Roth GmbH), sec-
tioned at 7 μm, and stained with Alcian blue (Sigma-
Aldrich) as an indicator of sulfated glycosaminoglycan
(sGAG)-rich extracellular matrix.
Statistical analysis
Statistical analysis was conducted utilizing Microsoft
Excel® 2010. Student’s t test was applied for comparing




After three passages following the retrieval of primary
culture, all of the cells displayed a typical adherent
spindle-shaped fibroblast-like morphology forming a
monolayer. Interestingly, in amnion samples of both spe-
cies, some colony-like spots of high cellular density were
observed. The antibodies against human antigens also
reacted with marmoset samples in immunohistochemical
staining displaying CD90+, CD105+, Snail1+, and Bra+, but
CD34− (Fig. 1a–j).Cellular proliferation capacity
When determining cellular viability and proliferation
capacity via the MTT test, amnion MSCs from both
Fig. 2 Evaluation of growth and metabolic activity of human and marmoset amnion and bone marrow-derived MSCs by the MTT test. Amnion-derived
cells from both species have significantly higher proliferation potential (p = 0.0133) in long-term culture, whereas human bone marrow MSCs could not
be expanded after day 60. MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Curve legends: a cjAmn - marmoset amnion,
hsAmn - human amnion, 3t3 - control 3t3 cell line; b cjBm - marmoset bone marrow, hsBm - human bone marrow, 3t3 - control 3t3 cell line
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MSCs (p = 0.0133, Student’s t test) and also notably bet-
ter than the immortalized NIH 3T3 cell line (Fig. 2a)
which was used as a control owing to its stable prolifera-
tive abilities. Furthermore, human bone marrow cells
stopped proliferation at 60 days of culture (Fig. 2b).
Surface marker analysis
Analysis by flow cytometry (Fig. 3a) showed that the
number of CD73+ cells did not significantly change in
marmoset amnion and bone marrow MSCs, 70.97 ± 0.54
at the early passage 3 compared with 74.43 ± 6.36 at the
late passage 12, but significantly increased in human am-
nion MSCs from 86.54 ± 0.99 at the early passages to
96.78 ± 0.43 at passage 12. In human bone marrow sam-
ples, the number of CD73+ cells was 86.44 ± 3.44 at the
early passages, significantly reducing to 67.4 ± 5.03 at
passage 12. Furthermore, numbers of CD105-positive
cells decreased significantly from passage 6 to passage
12 in the bone marrow samples of both species, from
99.26 ± 0.25 and 97.66 ± 1.19 to 83.46 ± 0.31 and 77.49 ±
3.51 in marmoset and human, respectively. In general, the
number of CD105+ cells in marmoset was generally sig-
nificantly lower than in human during all passages.
Quantitative PCR results for MSC markers and MHC class I
In quantitative PCR, CD90 mRNA expression signifi-
cantly decreased in all amnion MSC preparations during
passaging (in marmoset, expression at the early passages
was 3.27 ± 0.3-fold higher than in skin fibroblast control
and at the late passages was downregulated to −2.20 ±
0.44-fold; in the human, expression was 1.51 ± 0.09-fold
at passage 3 to −2.25 ± 0.62-fold at passage 12 respect-
ively), but significantly increased in the bone marrow
MSCs of both species (from 2.38 ± 0.18 at passage 3 to
4.56 ± 0.03 at passage 12 in marmoset, and from −4.41 ±1.37 at passage 3 to 3.62 ± 0.06 at passage 12 in human re-
spectively) (Fig. 3b). CD44 expression remained low and
stable in marmoset amnion and bone marrow MSCs and
in human bone marrow MSCs (Fig. 3c), but was signifi-
cantly upregulated in human amnion cells (at passage 3
expression is 14.9 ± 2.10-fold, at passage 6 expression is
16.15 ± 2.20-fold, and at passage 12 expression is 8.35 ±
1.25-fold vs. skin). Activated leukocyte cell adhesion
molecule (ALCAM, CD166) levels remained stable dur-
ing passaging in all studied samples except the human
bone marrow, where its expression was significantly
higher compared with all other samples at passage 3, be-
ing 21.00 ± 1.21 (Fig. 3d). Interestingly, vascular cell ad-
hesion molecule 1 (VCAM-1, CD106) expression was in
general significantly higher in marmoset tissues vs. hu-
man. The expression level was 127.18 ± 0.94 at the early
passages in marmoset amnion samples and 156.22 ± 1.99
in marmoset bone marrow samples at the early passages
and was downregulated respectively to 79.22 ± 3.34 and
82.16 ± 4.12 at the late passages. In contrast, even the ini-
tial expression of CD106 in the human samples at the
early passages was drastically lower than in marmoset
samples, being 36.32 ± 3.05 for amnion MSCs and 35.42 ±
3.71 for bone marrow MSCs (Fig. 3e), with further reduc-
tion in later passages in amnion samples.
Interestingly, the levels of MHC class I expression
(in case of the human also called HLA) at the early
passages were significantly lower in the amnion sam-
ples of both species in comparison with bone marrow.
Further, we detected a significant increase in positive
amnion cells of both species over time by FACS ana-
lysis (from 19.42 ± 0.43 at passage 3 to 79.47 ± 2.0 at
passage 12 in human, and from 31.35 ± 0.3 at passage
3 to 87.21 ± 4.0 at passage 12 in marmoset; Fig. 4a),
whereas roughly 80 % of bone marrow cells were posi-
tive for W6/32 antibody from the beginning at passage
Fig. 3 Analysis of typical mesenchymal markers. a Flow cytometry of CD73 and CD105. b–e Quantitative PCR of mesenchymal markers CD90,
CD44, CD166, and CD106 (2–ΔΔCt vs. skin). *Significant changes (Student’s t test, p ≤0.05)
Pogozhykh et al. Stem Cell Research & Therapy  (2015) 6:150 Page 8 of 153 and remained so until passage 12 (Fig. 4a) in both
species. This was in part reflected by quantitative PCR
results detecting expression of beta-2-microglobulin
(β2m) (Fig. 4b). Here, interestingly, marmoset expressed
overall significantly less β2m molecules independent of
tissue origin and passage when compared with human
(Fig. 4b).Quantitative PCR of pluripotency genes and bisulfide
sequencing
The existence of pluripotency genes in MSCs is controver-
sially discussed and very carefully determined by quantita-
tive PCR for typical pluripotency genes (Fig. 5a–f );
additionally, bisulfite sequencing of the Oct-4 promoter
region was performed (Fig. 5g–j). In our experiments,
Fig. 4 Evaluation of MHC class I expression by flow cytometry a and β2m by quantitative PCR b in MSCs. Amnion-derived cells from both species
seem to regain immunogenicity triggered by MHC class I over time, whereas bone marrow MSCs already show full expression of MHC class I at
passage 3. Interestingly, in marmoset expression of β2m is significantly lower than in human. *Significance by Student’s t test. β2m β2-microglobulin,
MHC major histocompatibility complex
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in all cell types. In marmoset amnion, at passage 3 Oct-4A
expressed 4.60 ± 2.38 and at passage 12 was only 1.14 ±
1.92-fold higher than in the control; in human amnion,
expression of Oct-4A is 9.16 ± 1.5 and decreases to 3.03 ±
1.59 at passage 12. The levels of expression of Oct-4A in
bone marrow do not differ significantly between the spe-
cies. They start at passage 3 with 11.02 ± 1.69 and 10.71 ±
1.67 and decrease at passage 12 to 1.68 ± 1.55 and 2.20 ±
1.60 in marmoset and human respectively. Nanog expres-
sion appeared to be at stably low yet detectable levels in
both species’ amnion MSCs, but significantly decreased in
human bone marrow MSCs from initial levels of 15.52 ±
1.46-fold vs. skin to 2.99 ± 1.6-fold (Fig. 5b). Interestingly,c-Myc expression was generally lower in all MSC types
(Fig. 5c) than in controls (skin), although slightly upregu-
lated at the early passages in marmoset amnion, whereas
Sox2 expression was significantly lower in marmoset
MSCs than in human MSCs with 27.53 ± 1.43-fold ex-
pression vs. skin at the early passage 3 in human amnion,
20.4 ± 1.47 in early passage in the bone marrow, decreas-
ing in both types of human MSCs significantly over time
to 15.01 ± 1.57 and 5.98 ± 1.53 respectively (Fig. 5d) at the
late passage 12. Complementary behavior was monitored
for Lin28A, which was much higher expressed in marmo-
set than in human. The initial level of expression of
Lin28A in marmoset amnion MSCs was 15.34 ± 1.53-fold
and was downregulated to 6.04 ± 1.53-fold at passage 12;
Fig. 5 (See legend on next page.)
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Fig. 5 Analysis of typical pluripotency (PP) markers a–f and methylation of Oct-4 promoter g–j. Expression of PP markers could be confirmed
(2–ΔΔCt vs. skin), primarily in early passages a, b. In general, Oct-4A represented the highest levels a, whereas Klf4 levels were very low f. As
expected, all pluripotency marker levels decrease over time. Interestingly, marmoset tissues display significantly lower Sox2 levels vs. human
f, but also significantly higher Lin28A levels e. *Significant change (Student’s t test). The nature of all PCR products was confirmed by DNA
sequencing. Methylation analysis of the Oct-4 promoter region revealed the heterogeneity within the cell populations: marmoset amnion MSCs
appeared to contain the most cells with an unmethylated pattern (open circles) g, whereas human amnion cells contained more methylated
(black circles) populations i
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creased to 9.65 ± 1.42 during passaging. In human sam-
ples, expression of Lin28A was significantly lower than in
the skin fibroblast controls. Klf4 levels were below skin
controls in all cell types, further decreasing with passa-
ging. An especially drastic decrease was observed in hu-
man bone marrow, with Klf4 mRNA −2.61 ± 1.43 at
passage 3 declining to −131.18 ± 1.45 at passage 12
(Fig. 5f). In all MSC preparations, a partially demethylated
Oct-4 promoter region could be detected (Fig. 5g–j).
Marmoset MSCs showed in general fewer methylation
sites than human MSCs.Differentiation experiments
All studied samples from both species were capable of
differentiation into adipogenic, osteogenic, and chondro-
genic mesenchymal lineages (Fig. 6). Human bone marrow
samples displayed the highest visual intensity of Alcian
blue staining (Fig. 6e).Discussion
Aim of the study
MSCs are the closest candidates for clinical application
in regenerative medicine, tissue engineering, and cell re-
placement therapy. Their excellent availability from various
sources, high plasticity, immunomodulatory properties,
and genetic integrity make them an ideal cell type for clin-
ical studies. Among these cells, bone marrow-derived, fat-
derived, and placental MSCs are highly attractive, owing to
availability of large-scale amounts of primary cell cultures
from these sources. Unfortunately, owing to the variety of
MSC sources and therefore heterogeneity of the obtained
MSC populations in primary cultures, results from differ-
ent research groups in terms of functions and general
characterization of MSCs are controversial, especially with
regard to pluripotency features of MSCs. Furthermore, lit-
tle is known about the differences and similarities of MSCs
of the common marmoset monkey in terms of surface
markers and gene expression, a readily used preclinical
nonhuman primate model in comparison with human. We
therefore performed a systematic study with MSCs derived
from the amnion of placenta and bone marrow from both
species to clarify characteristics, similarities, anddifferences of these cells between human and the common
marmoset.
Comparison of morphology and differentiation potential
Cells from both species and both origins showed typical
adherent spindle-shaped fibroblast-like morphology and
were capable of differentiating into adipocytes, chon-
drocytes, and osteogenic direction; adipogenic poten-
tial seems to be enhanced in bone marrow vs. amnion
MSCs in terms of vacuole size; and human bone mar-
row MSCs displayed the strongest Alcian blue staining.
These observations could be explained by niche-specific
differences.
MSC immunohistochemistry
All multipotent MSC lines of both species and origins
possessed typical marker combinations, CD44+, CD73+,
CD90+, CD105+, CD106+, CD166+, Snail1+, and Bra+,
but CD34− as reported by other studies [2, 22, 23].
Other groups report more CD73+ and CD105+ MSCs
found in the human bone marrow (roughly 98 %) vs. ap-
proximately 10–15 % lower numbers in placenta-derived
primary cultures [6], which is in accordance with our
data for human and marmoset. Various groups discuss
controversial results on the presence or absence of Bra-
chyury expression [22, 24]; in our case, both species and
MSC types showed positive signals in IHC.
Proliferation capacities
Our general duration of culture for amnion-derived
MSCs over 120 days (26 passages) corresponds with re-
sults from other groups of 140 days with 36.9 ± 4.7
population doublings [24], and human placenta-derived
MSCs have higher ex vivo proliferative capacity com-
pared with human bone marrow [6, 25]. This is interest-
ing from a biological point of view: the placenta itself is
a temporary organ, which completed its physiological
function at the moment of MSC isolation, but in our
case the bone marrow MSCs ceased proliferation after
day 60 in human. It could be speculated that such prolif-
eration capacity in both species is derermined by the im-
portance of placental functions for maintenance and
development of the embryo in case of injuries.
Fig. 6 Differentiation potential of human and marmoset MSCs of different origin. MSCs were differentiated into adipogenic a, d, g, j (Oil Red O),
chondrogenic b, e, h, k (Alcian Blue), and osteogenic c, f, i, l (Von Kossa) directions. Cells cultured in regular culture medium represent the
negative control. During adipogenic differentiation, bone marrow samples of both species formed visually larger lipid vacuoles in comparison
with amnion-derived cells d, j. Human amnion and human bone marrow samples showed higher visual intensity of Alcian blue staining b, e.
Osteogenic potential was visually the same in all studied samples c, f, i, l. Scale bar = 50 μm
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CD73 and CD105 are generally accepted mesenchymal
markers. CD73 (ecto-5′-nucleotidase) is additionally
found on the surface of human T and B lymphocytes,
facilitating in this case lymphocyte development and
function [26]. CD105 (endoglin) is a type I homodi-
meric transmembrane glycoprotein and a key recogni-
tion structure in cellular adhesion, expressed primarilyon vascular endothelial cells, chondrocytes, and syncy-
tiotrophoblasts of term placenta, suggesting a critical
role for endoglin in the binding of endothelial cells to
integrins and other RGD receptors [27]. The number of
CD73+ and CD105+ cells did not change significantly in
long-term culture in both species and origins except for
human bone marrow MSCs in passage 12 due to senes-
cence. Other groups report that CD73 and CD105 levels
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time [28], which might be due to different long-term
culture conditions.Quantitative PCR analysis of MSC markers
Additional commonly accepted MSC markers displayed
similarities and differences between the species and cellular
origins. CD90 (Thy-1), usually expressed in MSCs but also
in hematopoietic stem cells and fibroblasts, neurons, and
activated endothelial cells [27, 29], was slightly downregu-
lated in amnion MSC samples and upregulated in bone
marrow MSC samples of both studied species, which cor-
responds to the other results [30].
CD44 (hyaluronic acid receptor) is a cancer stem cell
marker and a potential pluripotency marker involved in
cell–matrix interaction, homing, adhesion, matrix as-
sembly, and apoptosis resistance [27, 31]. CD44 expres-
sion was significantly elevated in human amnion cells,
but was barely expressed in all other studied MSC sam-
ples of both species, which is in accordance with Kanda
et al. [30] but was not confirmed by Wagner et al. [28].
We speculate that these differences are due to different
methodological approaches (quantitative PCR vs. FACS).
CD166 is a widely used as a MSC marker with mul-
tiple functions such as cell–cell interactions, migration
and homing, neural development, hematopoiesis, im-
mune response, and tumor progression [27, 32]. In our
study, CD166 levels are generally significantly higher in
bone marrow MSCs due to their role in hematopoiesis,
but in general significantly lower in the marmoset, which
is a species-specific difference.
CD106 is a cell surface sialoglycoprotein connected
with homing, migration, and adhesion of cultured cells
[27, 33, 34] and a controversial history of presence and
absence in the literature [9, 12]. In our study, levels of
CD106 in the nonhuman primate were generally signifi-
cantly higher in comparison with human samples, a
species-specific difference which could be explained by
the immunomodulatory role of this molecule in a natur-
ally chimeric animal like C. jacchus.MHC class I expression
A major difference of bone marrow and amnion MSCs is
their lack of MHC class I molecules on the surface, making
them perfect candidates for potential clinical application
owing to reduced immune responses during allogeneic
transplantations [25, 35]. This potential could be confirmed
in our study for human and marmoset, where all bone mar-
row MSCs displayed high MHC class I levels from passage
3 onwards. It should be mentioned that MSCs also display
other immunosuppressing strategies than MHC class I sup-
pression [36], such as suppression of CD4+ and CD8+ T-
lymphocyte proliferation by the arrest anergy of T cells inthe G0/G1 phase of the cell cycle [37]. Furthermore, and
marmoset specific, we found a significant reduction of β2m
molecules, which might be explained by the superior im-
mune adaptation of the marmoset as a monoplacental ani-
mal with chimeric features. Some authors suggest that this
tolerance is primarily due to tryptophan catabolizing en-
zyme indoleamine 2,3-dioxygenase (IDO) and HLA-G mol-
ecules binding to two major inhibitory natural killer (NK)
receptors, killer-cell immunoglobulin-like receptors KIR1
and KIR2, thus inhibiting NK killing [25, 38, 39]. For the fu-
ture it would be interesting to investigate whether bone
marrow and amnion MSCs generally utilize different or
synergistic strategies to evade the immune responses and
whether the reduced β2m expression in the marmoset can
also be found in other tissues.
Presence of pluripotency markers
There is much debate about the presence or absence
of pluripotency marker genes in MSCs in general
[12, 14, 40–42]. In our study, the key player (Oct-4A) was
clearly present during early passaging but decreased, as
expected, over time in all MSC types. In accordance with
this, bisulfite sequencing of the Oct-4 promoter region
showed high heterogeneity in primary cultures of all stud-
ied cell types. We speculate from these observations that
there might exist a small population of cells with a ten-
dency for pluripotency in primary MSC cultures decreas-
ing rapidly owing to suboptimal culture conditions. Sox2
and Nanog were expressed significantly higher in the pla-
cental samples in comparison with the bone marrow [9],
whereas other groups showed decreased expression in
middle and later passages of chorion MSCs [43]. In our
study, detectable levels of Nanog were found in both hu-
man and nonhuman primate, remaining surprisingly con-
stant over passaging except for the human bone marrow
samples owing to the mentioned senescence.
Presence of Sox2 is also reported controversially [43],
but decreased in our study significantly over time in cells
of both species and cellular origins. However, Sox2 ex-
pression was significantly lower in marmoset MSCs than
in human, which is not reflected in the literature and
might be a specific difference between the species. Inter-
estingly, Lin28A expression, a factor which is found in
early embryogenesis, in primordial germ cells, in ESCs,
and also in some adult tissues [44], was significantly
higher in marmoset samples than in human. Presence of
Lin28A was shown to have an impact on reprogramming
efficiency in human and is subsequently required for the
stable expansion of reprogrammed cells in human [45]
and in marmoset [46] but is not expressed in human
somatic cell lines [47]. c-Myc and Klf4 induce transcrip-
tional regulation and have a great impact on MSC differ-
entiation. Additionally, Klf4 has been shown to regulate
MSC transcriptional activity and maintain cells in the
Pogozhykh et al. Stem Cell Research & Therapy  (2015) 6:150 Page 14 of 15undifferentiated state [48, 49]. In our experiments, Klf4
levels were below skin controls in all cell types and also
c-Myc expression was very weak in all MSC cultures.
In summary, indications of “stemness” were observed
in early passages of both amnion and bone marrow-
derived MSCs from human and marmoset. However, the
expression level of Sox2 was significantly lower and ex-
pression of Lin28A was significantly higher in the non-
human primate.
Conclusions
Application of stem cell therapy in treating various
autoimmune and neurodegenerative diseases is rapidly
progressing. Since the usage of highly pluripotent ESCs
and iPSCs in clinics is exceedingly complicated by legis-
lative, ethical, and safety issues, numerous studies are
focused on application of MSCs and hematopoietic stem
cells as a therapeutic tool being the most feasible ap-
proach for the purposes of regenerative medicine. How-
ever, adequate preclinical animal models are required to
study long-term outcome in terms of graft rejection and
efficiency of cellular therapies.
Our major findings in this manuscript are the following:
human and marmoset cells share most common MSC fea-
tures, and thus a small nonhuman primate common mar-
moset proves to be a valid preclinical model also in the
field of MSC research; amnion MSCs of both species have
higher proliferation activity in comparison with bone mar-
row MSCs, thus making them superior candidates for ex-
pansion; amnion MSCs of both species display low MHC
class I expression in early passages, whereas bone marrow
MSCs have significantly higher MHC class I levels from
the very beginning, indicating a potential disadvantage in
the case of transplantation; and all studied types of MSCs
express certain levels of pluripotency markers, with differ-
ences in Lin28 and Sox2 expression between the species.
Taken together with findings on demethylated Oct-4 pro-
moter regions, we speculate that a small subpopulation of
still pluripotent cells might be present in early passages.
The developmental origin of these cells remains unclear
and would require further investigation. In summary,
we believe that the potential of placenta-derived MSCs
is greatly underrated, particularly in terms of pluripo-
tency and immunology. If this postulated pluripotent
amnion cell subpopulation could be stabilized by cul-
tural methods, the genetic and technical problems of
virally induced pluripotent cells could be easily over-
come in the future with a cell source that can be ob-
tained noninvasively and is patient specific.
Abbreviations
ALCAM: Activated leukocyte cell adhesion molecule; CD: Cluster of
differentiation; CeRA: Centre of Reproductive Medicine and Andrology;
ddH2O: Double-distilled water; DMEM: Dulbecco’s Modified Eagle Medium;
EDTA: Ethylenediamine tetracetic acid; ELISA: Enzyme-linked immunosorbentassay; ESC: Embryonic stem cell; FACS: Fluorescence-activated cell sorting;
FCS: Fetal calf serum; FGF: Fibroblast growth factor; HLA: Human leukocyte
antigen; IDO: Indoleamine 2,3-dioxygenase; IHC: Immunohistochemistry;
iPSC: Induced pluripotent stem cell; KIR: killer-cell immunoglobulin-like
receptor; MHC: Major histocompatibility complex; MSC: Multipotent stromal
cell; MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
NK: Natural killer; PBS: Phosphate-buffered saline; sGAG: Sulfated
glycosaminoglycan; VCAM: Vascular cell adhesion molecule;
β2m: Beta-2-microglobulin.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
OP designed the study, carried out cell culture maintenance, performed
molecular genetic studies, implemented statistical analysis, and drafted the
manuscript. DP assisted in cell culture maintenance, performed the metabolic
activity test, carried out and analyzed bisulfite sequencing, and drafted the
manuscript. A-LN carried out titration and efficiency of primers for real-time PCR
and helped to revise the manuscript. AH prepared and provided human bone
marrow stem cells for the study and revised the manuscript. RB gave approval
for the study design, revised the data and manuscript, and approved the final
version to be published. TM designed and coordinated the study, and participated
in data analysis and manuscript writing. All authors read and approved the final
manuscript.
Acknowledgements
The authors thank Kirsten Elger for excellent technical support. Their gratitude
also includes Prof. Stefan Schlatt and the CeRA for providing us with material
from the common marmoset and Dr M Imamura and Dr YZ Lin for methodical
help with methylation profiling.
Author details
1Institute for Transfusion Medicine, Hannover Medical School,
Carl-Neuberg-Straße 1, 30625 Hannover, Germany. 2Department of
Orthopaedic Surgery, Hannover Medical School, Anna-von-Borries-Straße 1-7,
30625 Hannover, Germany.
Received: 23 February 2015 Revised: 24 February 2015
Accepted: 5 August 2015
References
1. Macias MI, Grande J, Moreno A, Dominguez I, Bornstein R, Flores AI. Isolation
and characterization of true mesenchymal stem cells derived from human
term decidua capable of multilineage differentiation into all 3 embryonic
layers. Am J Obstet Gynecol. 2010;203:495.e9–e23.
2. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,
et al. Minimal criteria for defining multipotent mesenchymal stromal cells.
The International Society for Cellular Therapy position statement.
Cytotherapy. 2006;8:315–7.
3. Mafi R, Hindocha S, Mafi P, Griffin M, Khan WS. Sources of adult mesenchymal
stem cells applicable for musculoskeletal applications—a systematic review of
the literature. Open Orthop J. 2011;5:242–8.
4. Barlow S, Brooke G, Chatterjee K, Price G, Pelekanos R, Rossetti T, et al.
Comparison of human placenta- and bone marrow-derived multipotent
mesenchymal stem cells. Stem Cells Dev. 2008;17:1095–107.
5. Wegmeyer H, Broske AM, Leddin M, Kuentzer K, Nisslbeck AK, Hupfeld J,
et al. Mesenchymal stromal cell characteristics vary depending on their
origin. Stem Cells Dev. 2013;22:2606–18.
6. Jaramillo-Ferrada PA, Wolvetang EJ, Cooper-White JJ. Differential mesengenic
potential and expression of stem cell-fate modulators in mesenchymal stromal
cells from human-term placenta and bone marrow. J Cell Physiol.
2012;227:3234–42.
7. Hass R, Kasper C, Bohm S, Jacobs R. Different populations and sources of
human mesenchymal stem cells (MSC): a comparison of adult and neonatal
tissue-derived MSC. Cell Commun Signal. 2011;9:12.
8. Yoshizawa RS. Review: Public perspectives on the utilization of human
placentas in scientific research and medicine. Placenta. 2013;34:9–13.
Pogozhykh et al. Stem Cell Research & Therapy  (2015) 6:150 Page 15 of 159. Sabapathy V, Ravi S, Srivastava V, Srivastava A, Kumar S. Long-term cultured
human term placenta-derived mesenchymal stem cells of maternal origin
displays plasticity. Stem Cells Int. 2012;174328.
10. Weiss ML, Troyer DL. Stem cells in the umbilical cord. Stem Cell Rev.
2006;2:155–62.
11. Semenov OV, Koestenbauer S, Riegel M, Zech N, Zimmermann R, Zisch AH, et al.
Multipotent mesenchymal stem cells from human placenta: critical parameters
for isolation and maintenance of stemness after isolation. Am J Obstet Gynecol.
2010;202:193.e1–e13.
12. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical
cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem
Cells. 2005;23:220–9.
13. Leeb C, Jurga M, McGuckin C, Moriggl R, Kenner L. Promising new sources
for pluripotent stem cells. Stem Cell Rev. 2010;6:15–26.
14. Koike C, Zhou K, Takeda Y, Fathy M, Okabe M, Yoshida T, et al. Characterization
of amniotic stem cells. Cell Reprogram. 2014;16:298–305.
15. Mansfield K. Marmoset models commonly used in biomedical research.
Comp Med. 2003;53:383–92.
16. Sasaki E, Hanazawa K, Kurita R, Akatsuka A, Yoshizaki T, Ishii H, et al.
Establishment of novel embryonic stem cell lines derived from the
common marmoset (Callithrix jacchus). Stem Cells. 2005;23:1304–13.
17. Mueller T, Fleischmann G, Horn P, Sasaki E, Behr R. A novel primate ES cell
line from the common marmoset (Callithrix jacchus) exhibits germ cell
development in vitro. J Stem Cells Regen Med. 2007;2:81–2.
18. Wiedemann A, Hemmer K, Bernemann I, Gohring G, Pogozhykh O, Figueiredo C,
et al. Induced pluripotent stem cells generated from adult bone marrow-derived
cells of the nonhuman primate (Callithrix jacchus) using a novel quad-cistronic
and excisable lentiviral vector. Cell Reprogram. 2012;14:485–96.
19. Wu Y, Mishra A, Qiu Z, Farnsworth S, Tardif SD, Hornsby PJ. Nonhuman primate
induced pluripotent stem cells in regenerative medicine. Stem Cells Int.
2012;2012:767195.
20. Schack LM, Noack S, Weist R, Jagodzinski M, Krettek C, Buettner M, et al.
Analysis of surface protein expression in human bone marrow stromal cells:
new aspects of culture-induced changes, inter-donor differences and
intracellular expression. Stem Cells Dev. 2013;22:3226–35.
21. Lin ZY, Imamura M, Sano C, Nakajima R, Suzuki T, Yamadera R, et al.
Molecular signatures to define spermatogenic cells in common marmoset
(Callithrix jacchus). Reproduction. 2012;143:597–609.
22. Moon JH, Lee JR, Jee BC, Suh CS, Kim SH, Lim HJ, et al. Successful
vitrification of human amnion-derived mesenchymal stem cells. Hum
Reprod. 2008;23:1760–70.
23. Batlle R, Alba-Castellon L, Loubat-Casanovas J, Armenteros E, Franci C,
Stanisavljevic J, et al. Snail1 controls TGF-beta responsiveness and
differentiation of mesenchymal stem cells. Oncogene. 2013;32:3381–9.
24. Kim Y, Kim H, Cho H, Bae Y, Suh K, Jung J. Direct comparison of human
mesenchymal stem cells derived from adipose tissues and bone marrow in
mediating neovascularization in response to vascular ischemia. Cell Physiol
Biochem. 2007;20:867–76.
25. Deuse T, Stubbendorff M, Tang-Quan K, Phillips N, Kay MA, Eiermann T,
et al. Immunogenicity and immunomodulatory properties of umbilical cord
lining mesenchymal stem cells. Cell Transplant. 2011;20:655–67.
26. Yamashita Y, Hooker SW, Jiang H, Laurent AB, Resta R, Khare K, et al. CD73
expression and fyn-dependent signaling on murine lymphocytes. Eur J
Immunol. 1998;28:2981–90.
27. Shiffman MAGA, Bassetto F, editors. Stem cells in aesthetic procedures: art,
science, and clinical techniques. Heidelberg: Springer; 2014.
28. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, et al.
Replicative senescence of mesenchymal stem cells: a continuous and
organized process. PLoS One. 2008;3, e2213.
29. Kisselbach L, Merges M, Bossie A, Boyd A. CD90 Expression on human
primary cells and elimination of contaminating fibroblasts from cell cultures.
Cytotechnology. 2009;59:31–44.
30. Kanda A, Sotomaru Y, Nobukiyo A, Yamaoka E, Hiyama E. Characterization of
common marmoset (Callithrix jacchus) bone marrow-derived mesenchymal
stem cells. Folia Histochem Cytobiol. 2013;51:292–9.
31. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly
expressed molecule? Nat Rev Cancer. 2011;11:254–67.
32. Swart GW. Activated leukocyte cell adhesion molecule (CD166/ALCAM):
developmental and mechanistic aspects of cell clustering and cell
migration. Eur J Cell Biol. 2002;81:313–21.33. Jung EM, Kwon O, Kwon KS, Cho YS, Rhee SK, Min JK, et al. Evidences for
correlation between the reduced VCAM-1 expression and hyaluronan
synthesis during cellular senescence of human mesenchymal stem cells.
Biochem Biophys Res Commun. 2011;404:463–9.
34. Abumaree MH, Al Jumah MA, Kalionis B, Jawdat D, Al Khaldi A, AlTalabani AA,
et al. Phenotypic and functional characterization of mesenchymal stem cells
from chorionic villi of human term placenta. Stem Cell Rev. 2013;9:16–31.
35. Bacenkova D, Rosocha J, Tothova T, Rosocha L, Sarissky M. Isolation and
basic characterization of human term amnion and chorion mesenchymal
stromal cells. Cytotherapy. 2011;13:1047–56.
36. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA
expression and immunologic properties of differentiated and
undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890–6.
37. Benvenuto F, Ferrari S, Gerdoni E, Gualandi F, Frassoni F, Pistoia V, et al.
Human mesenchymal stem cells promote survival of T cells in a quiescent
state. Stem Cells. 2007;25:1753–60.
38. Averdam A, Kuhl H, Sontag M, Becker T, Hughes AL, Reinhardt R, et al. Genomics
and diversity of the common marmoset monkey NK complex. J Immunol.
2007;178:7151–61.
39. Gomez-Lozano N, de Pablo R, Puente S, Vilches C. Recognition of HLA-G by
the NK cell receptor KIR2DL4 is not essential for human reproduction. Eur J
Immunol. 2003;33:639–44.
40. Yannarelli G, Pacienza N, Cuniberti L, Medin J, Davies J, Keating A. Brief
report: The potential role of epigenetics on multipotent cell differentiation
capacity of mesenchymal stromal cells. Stem Cells. 2013;31:215–20.
41. Moschidou D, Mukherjee S, Blundell MP, Drews K, Jones GN, Abdulrazzak H,
et al. Valproic acid confers functional pluripotency to human amniotic fluid
stem cells in a transgene-free approach. Mol Ther. 2012;20:1953–67.
42. Moschidou D, Mukherjee S, Blundell MP, Jones GN, Atala AJ, Thrasher AJ,
et al. Human mid-trimester amniotic fluid stem cells cultured under
embryonic stem cell conditions with valproic acid acquire pluripotent
characteristics. Stem Cells Dev. 2013;22:444–58.
43. Fariha MM, Chua KH, Tan GC, Tan AE, Hayati AR. Human chorion-derived
stem cells: changes in stem cell properties during serial passage.
Cytotherapy. 2011;13:582–93.
44. Aeckerle N, Drummer C, Debowski K, Viebahn C, Behr R. Primordial germ
cell development in the marmoset monkey as revealed by pluripotency
factor expression: suggestion of a novel model of embryonic germ cell
translocation. Mol Hum Reprod. 2015;21:66–80.
45. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S,
et al. Induced pluripotent stem cell lines derived from human somatic cells.
Science. 2007;318:1917–20.
46. Tomioka I, Takahashi T, Shimada A, Yoshioka K, Sasaki E. Birth of common
marmoset (Callithrix jacchus) offspring derived from in vitro-matured
oocytes in chemically defined medium. Theriogenology. 2012;78:1487–93.
47. Vogt EJ, Meglicki M, Hartung KI, Borsuk E, Behr R. Importance of the
pluripotency factor LIN28 in the mammalian nucleolus during early
embryonic development. Development. 2012;139:4514–23.
48. Roson-Burgo B, Sanchez-Guijo F, Del Canizo C, De Las Rivas J. Transcriptomic
portrait of human mesenchymal stromal/stem cells isolated from bone marrow
and placenta. BMC Genomics. 2014;15:910.
49. Fan W, Crawford R, Xiao Y. The ratio of VEGF/PEDF expression in bone
marrow mesenchymal stem cells regulates neovascularization.
Differentiation. 2011;81:181–91.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
